Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.31 - $61.19
Previous CloseN/A
Volume107.14K
Average Volume (3M)2.96M
Market Cap
$7.26B
Enterprise Value$3.95B
Total Cash (Recent Filing)$858.13M
Total Debt (Recent Filing)$858.06M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Oct 30, 2025EPS Estimate
-1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding119,657,160
10 Day Avg. Volume2,302,073
30 Day Avg. Volume2,956,563
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.54
Enterprise Value/Revenue46.01
Enterprise Value/Gross Profit-20.27
Enterprise Value/Ebitda-7.81
Forecast
1Y Price Target
$80.64Price Target Upside34.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Efficacy And Tolerability96-week analyses from FOREST-HCM continue to show long-term efficacy and tolerability of aficamten in nHCM.
Financial PerformanceCytokinetics executed on a $650M upsized convertible note offering to refinance the majority portion of the 2027 convertible notes into 2031, at an attractive 1.75% coupon rate and conversion price at ~38% premium to $50 share price.
Market Launch And GrowthHFSA'25 and AHA'25 conferences' incremental data disclosures represent significant tailwinds to Cytokinetics launching aficamten, representing likely upside to relatively conservative estimates.
Bears Say
Placebo Response ConcernsThe placebo response in recent trials remains an important open question, showing higher-than-expected improvements.
Uncertainty In Trial ResultsWith no concerns flagged during the Late Cycle Meeting, the narrative is moving toward the role of MAPLE-HCM in accelerating uptake and the potential for indication expansion with ACACIA topline data.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $61.19 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $7.26B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 30, 2025 which is in 22 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 07, 2025. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.43 by $0.31.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.57.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 119,657,160 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.43. Following the earnings report the stock price went down -3.234%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.64 (34.02% Upside)
$80.64 (34.02% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 118.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.47%
12-Months-Change
Fundamentals
Return on Equity
435.49%
Trailing 12-Months
Asset Growth
-19.57%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant advancements in clinical trials, regulatory progress, and sales force readiness. However, these were countered by financial challenges, including increased expenses and a net loss, as well as a delayed PDUFA date impacting timelines for aficamten's approval.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$80.64
▲(34.02% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
0.80% Insiders
36.74% Mutual Funds
0.48% Other Institutional Investors
37.92% Public Companies and
Individual Investors